Clinical Trial Update: D9319C00001- 1L OC Mono Global RCT [Phase 3]

View source ↗

Summary

Phase 3 global randomized trial of a monotherapy in first-line ovarian cancer is currently active but not recruiting. Sponsor: AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING